|
Jan 1
|
Arvinas, Inc. (ARVN) Just Flashed Golden Cross Signal: Do You Buy?
|
|
Jan 1
|
Is Arvinas (ARVN) Outperforming Other Medical Stocks This Year?
|
|
Dec 27
|
TipRanks’ ‘Perfect 10’ List: These 3 Top-Scoring Stocks Are Poised to Perform in 2024
|
|
Dec 18
|
12 Most Promising Cancer Stocks According to Analysts
|
|
Dec 6
|
Pfizer (PFE), Arvinas Post Upbeat Data From Breast Cancer Study
|
|
Dec 6
|
Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program
|
|
Dec 5
|
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
|
|
Dec 1
|
Does Arvinas, Inc. (ARVN) Have the Potential to Rally 145.52% as Wall Street Analysts Expect?
|
|
Nov 28
|
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
|
|
Nov 27
|
Arvinas Announces Oversubscribed $350 Million Private Placement
|
|
Nov 7
|
Arvinas Inc (ARVN) Reports Q3 2023 Financial Results and Provides Corporate Update
|
|
Nov 7
|
Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update
|
|
Jun 29
|
Goldman Sachs Says Attractive Valuations Make Small-Cap Stocks Appealing; Here Are 2 ‘Strong Buy’ Names With Solid Upside Potential
|